Testosterone prescribing and persistence among adult females: a new-user cohort study
The Journal of Clinical Endocrinology & Metabolism · 10.11.2026
DOI: 10.1210/clinem/dgag444 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 10.11.2026. Verfasst von Sarah C J Jorgensen und 1 weiteren Autor:innen. Beteiligte Einrichtung: Center for Clinical Epidemiology and Population Health, Marshfield Clinic Research Institute, Marshfield, WI, United States. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 63 Literaturangaben. Gefördert von: Marshfield Clinic Research Institute, Sanford Health Foundation.
Abstract (Originalsprache)
Context
Testosterone use among females has risen recently, partly fueled by consumer-directed marketing for a wide range of unsupported indications. Hypoactive sexual desire disorder (HSDD) in postmenopausal females remains the only evidence-based indication.
Objectives
To describe characteristics of females initiating testosterone, indications, temporal trends, serum concentration monitoring, and duration of therapy.
Methods
Retrospective new-user cohort study using TriNetX de-identified electronic health record (EHR) data. Adult females newly prescribed testosterone from 2016 to 2024 were included. Patients with gender incongruence were excluded.
Results
In total, 10 185 females were included; median age 52 (42-59) years. Cardiac disease, ≥1 psychiatric diagnosis, and a history of breast or gynecological cancer were documented in 20%, 36%, 3.1%, and 2.8%, respectively. HSDD was documented in 17%. The annual percentage change in new testosterone users was 7.5% (95% CI, −1.0% to 10%) from 2016 to 2022 and 22% (95% CI, 12-29%) from 2022 to 2024. The prevalence of testosterone serum concentration monitoring was 16% at baseline and 10% at 60 to 180 days. Concentrations >70 ng/dL were documented in 38% of those tested at follow-up. Fifty-nine percent received a single testosterone prescription; among those with ≥2 prescriptions, the median time to discontinuation was 19.3 months (95% CI, 18.8-20.0).
Conclusion
New testosterone use among females increased over the study period, it was most often prescribed without a documented HSDD diagnosis, many had preexisting conditions excluded from clinical trials, monitoring reported in the EHR was low, and concentrations >70 ng/dL were documented in 38% of those tested. Among those who continued therapy, a substantial proportion persisted beyond 24 months for which limited safety data are available.
Autor:innen und Institutionen
- Center for Clinical Epidemiology and Population Health, Marshfield Clinic Research Institute, Marshfield, WI, United States.
ORCID-Profile: Sarah C J Jorgensen
Förderung
- Marshfield Clinic Research Institute
- Sanford Health Foundation
Zitieren
APA
Jorgensen, S. C. J., & McClure, D. L. (2026). Testosterone prescribing and persistence among adult females: a new-user cohort study. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgag444
Vancouver
Jorgensen SCJ, McClure DL. Testosterone prescribing and persistence among adult females: a new-user cohort study. The Journal of Clinical Endocrinology & Metabolism. 2026. doi:10.1210/clinem/dgag444
BibTeX
@article{Jorgensen2026,
author = {Jorgensen, Sarah C J and McClure, David L},
title = {Testosterone prescribing and persistence among adult females: a new-user cohort study},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2026},
doi = {10.1210/clinem/dgag444}
}
EUVIMED